Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (Nasdaq: KURA) is a biopharmaceutical company focused on precision medicines for cancer, and its news flow reflects the evolution of this strategy. Company announcements highlight progress with KOMZIFTI (ziftomenib), an oral menin inhibitor approved in the United States for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.
News items for KURA commonly cover regulatory milestones, clinical data and commercial updates. Recent releases describe full FDA approval of KOMZIFTI, its addition to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as a Category 2A recommended option for relapsed or refractory NPM1-mutated AML, and the start of U.S. commercial sales. Kura also reports on its collaboration with Kyowa Kirin, including milestone payments tied to clinical and commercial events.
Investors following KURA news can expect detailed coverage of clinical trial readouts from programs such as KOMET-001, KOMET-007 and KOMET-017, which evaluate ziftomenib across newly diagnosed and relapsed or refractory AML, often in combination with regimens like cytarabine/daunorubicin and venetoclax/azacitidine. Additional news addresses the company’s farnesyl transferase inhibitor programs, darlifarnib and tipifarnib, and their activity in solid tumors.
Kura’s press releases also include corporate updates such as financial results, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in scientific and investor conferences. For readers tracking KURA, this news page offers a centralized view of key developments in its precision oncology pipeline, regulatory interactions, collaborations and commercialization activities.
Kura Oncology (Nasdaq: KURA) will participate in the Bank of America Securities 2026 Healthcare Conference on May 13, 2026. Management is scheduled for a fireside chat at 6:00 p.m. ET / 3:00 p.m. PT. A live webcast and archived replay will be available on the company Investors website.
Kura Oncology (Nasdaq: KURA) will report first quarter 2026 financial results after market close on Tuesday, May 12, 2026. Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss results and provide a corporate update. A live webcast and archived replay will be available on the company Investors website.
Kura Oncology (Nasdaq: KURA) announced that on May 1, 2026 its Compensation Committee granted inducement nonstatutory stock options to five new employees to purchase 133,750 shares under the 2023 Inducement Option Plan, as amended.
Each option has an exercise price of $8.77 (closing price on May 1, 2026) and vests over four years (25% at one year, then monthly over 36 months), subject to continued service and applicable plan and agreement terms.
Kura Oncology (Nasdaq: KURA) reported preliminary subset data (N=16) showing the combination of darlifarnib plus cabozantinib produced a 44% objective response rate and 94% disease control rate in cabozantinib‑pretreated clear cell renal cell carcinoma (ccRCC) patients.
Tumor shrinkage occurred in 75% of patients, reductions ranged 32%–47% among responders, treatment durations reached 56 weeks, and six patients remained on therapy at data cut‑off. Safety was described as manageable across dose levels.
Kura Oncology (Nasdaq: KURA) will present updated Phase 1 FIT-001 data showing that darlifarnib combined with cabozantinib produced encouraging clinical activity and a manageable safety profile in advanced clear cell renal cell carcinoma patients previously treated with cabozantinib.
The presentation is scheduled for April 17, 2026 at IKCS Europe 2026; a virtual investor webcast and replay will follow at 7:30 a.m. PT / 10:30 a.m. ET.
Kura Oncology (Nasdaq: KURA) announced that on April 1, 2026 its Compensation Committee granted inducement nonstatutory stock options to six new employees totaling 153,750 shares under the 2023 Inducement Option Plan, as amended.
Each option has an $8.34 exercise price (April 1, 2026 closing price) and vests over four years: 25% at one year, then monthly over 36 months, subject to continued service and plan terms.
Kura Oncology (Nasdaq: KURA) announced that on March 2, 2026 the Compensation Committee granted inducement nonstatutory stock options to four new employees totaling 44,700 shares under the company’s 2023 Inducement Option Plan, as amended.
Each option has an exercise price of $8.68 (closing price on March 2, 2026) and vests over four years: 25% after one year and the remainder monthly over 36 months, subject to continued service and plan terms.
Kura Oncology (Nasdaq: KURA) reported Q4 and full-year 2025 results and a corporate update on March 5, 2026. Key highlights: KOMZIFTI FDA-approved for R/R NPM1-mutant AML, generated $2.1M in Q4 product revenue, and achieved Orange Book patent protection through July 2044. Company ended 2025 with $667.2M in cash and expects $180M in collaboration payments to fund KOMET-017 through topline Phase 3 results anticipated in 2028.
Pipeline advances include pivotal KOMET-017 frontline trials, FIT-001 Phase 1b expansion, and multiple 2026 clinical data milestones across AML and solid tumors.
Kura Oncology (Nasdaq: KURA) will report its fourth quarter and full year 2025 financial results on Thursday, March 5, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss results and a corporate update.
Investors can access the live webcast and archived replay via the Investors section of the company website at www.kuraoncology.com.
Kura Oncology (Nasdaq: KURA) will participate in three investor conferences in March 2026: TD Cowen Health Care Conference on March 4 at 11:50 a.m. ET, Leerink Partners Global Biopharma Conference on March 10 at 10:40 a.m. ET, and Barclays Global Healthcare Conference on March 12 at 9:00 a.m. ET.
Live audio webcasts will be available in the Investors section of Kura’s website, with archived replays posted after each event.